Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
100 participants
INTERVENTIONAL
2025-06-16
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Dobutamine on Hepatic Blood Flow During Goal-directed Hemodynamic Therapy
NCT04893655
Determination of the ED50 and ED95 of Prophylactic Norepinephrine Infusion for Preventing Post-induction Hypotension in Elderly Patients Undergoing Major Abdominal Surgery
NCT05637164
Influence of Different Parameters on Extubation Time After Cardiac Surgery.
NCT03309280
Intraoperative Goal-directed Blood Pressure and Dexmedetomidine on Outcomes
NCT03933306
Arterial dP/dt Dependency on Loading Conditions
NCT06164405
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dobutamine administration
In patient assigned to dobutamine administration, dobutamine (concentration: 5 mg mL-1) will be administered with an infusion rate of 3 µg kg-1 min-1 (ideal body weight).
Dobutamine administration will start with the beginning of surgery and will end after the end of surgery (incision-to-suture). The treating anesthesiologist may increase or stop dobutamine administration if clinically indicated. Whenever dobutamine-induced tachycardia (defined as a heart rate ≥120 beats per minute) or new-onset cardiac arrhythmia is noted, dobutamine administration will be stopped. Restarting dobutamine administration is at the discretion of the treating anesthesiologist.
Dobutamine
In patient assigned to dobutamine administration, dobutamine (concentration: 5 mg mL-1) will be administered with an infusion rate of 3 µg kg-1 min-1 (ideal body weight).
Routine care
In patients assigned to routine care, intraoperative hemodynamic management will be in accordance with routine care.
Routine care
In patients assigned to routine care, intraoperative hemodynamic management will be in accordance with routine care.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dobutamine
In patient assigned to dobutamine administration, dobutamine (concentration: 5 mg mL-1) will be administered with an infusion rate of 3 µg kg-1 min-1 (ideal body weight).
Routine care
In patients assigned to routine care, intraoperative hemodynamic management will be in accordance with routine care.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Planned continuous intraarterial blood pressure monitoring using an arterial catheter for clinical indications not related to the trial
Exclusion Criteria
* Liver or kidney transplantation surgery
* Status of post transplantation of kidney, liver, heart, or lung
* Pregnancy
* Heart rhythms other than sinus rhythm
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Hamburg-Eppendorf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Alina Bergholz
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alina Bergholz, MD
Role: PRINCIPAL_INVESTIGATOR
University Medical Centre Hamburg-Eppendorf
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Center Hamburg-Eppendorf
Hamburg, City state of Hamburg, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Bernd Saugel, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Karim Kouz, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-100915-BO-ff
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.